

Supporting Information

for

Selectively charged and zwitterionic analogues of the smallest immunogenic structure of *Streptococcus pneumoniae* type 14

Tiziana Gragnani¹, Doretta Cuffaro¹, Silvia Fallarini², Grazia Lombardi², Felicia D'Andrea^{1,*}, Lorenzo Guazzelli^{1,*}

¹Dipartimento di Farmacia, University of Pisa, Via Bonanno 6/33, 56126, Pisa, Italy

²Dipartimento di Scienze del Farmaco, University of Piemonte Orientale "Amedeo Avogadro", Largo Donegani 2, 28100 Novara, Italy

Corresponding Authors:

Lorenzo Guazzelli, E-mail: lorenzo.guazzelli@unipi.it;

Felicia D'Andrea, E-mail: felicia.dandrea@unipi.it.

Contents

Experimental procedures, characterization data of 10-23	S2-S9
Experimental procedures, characterization data of 25-28	S9-S12
Experimental procedures, characterization data of 31-40	S12-S19
References	S19
NMR spectra of new compounds	S21-S83

Experimental procedures and characterization data of 10-23.

General procedure A for the de-O-isopropylidenation of 11-12 and 14-15:

The appropriate protected sugar (1 mmol) was dissolved in 70% aq AcOH (13 mL) and heated to 40 °C while stirring until TLC analysis (TLC, EtOAc or 9:1 CHCl₃-MeOH, 3-5 h) revealed the complete disappearance of the starting material and formation of a more retained product. The solution was then cooled to room temperature and coevaporated with toluene (4×20 mL) under diminished pressure. The crude product was purified by flash chromatography on silica gel.

General procedure B for the regioselective protection with *tert*-butyldimethylsilyl chloride (TBDMSCl) at C-6 of 16-19:

A solution of the appropriate diol (**16-19**) (1 eq) in dry pyridine (7.0 mL) treated with TBDMSCl (2 eq) and the solution was left to react at room temperature until TLC analysis (TLC, 1:1 hexane- EtOAc or EtOAc) showed complete disappearance of the starting material (2-4 h) and formation of a slower moving product. The reaction was diluted with CHCl₃, washed with satd aq NaHCO₃ and then brine. The organic phase was dried, filtered and concentrated under diminished pressure. The crude product was purified by flash chromatography on silica gel.

Methyl 2-acetamido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside (**10**).

A solution of known **8** [1] (5.37 g, 22.8 mmol) in dry DMF (83 mL) was cooled at 0 °C and treated with freshly distilled 2-methoxypropene (6.6 mL, 68.4 mmol, 3 eq) and camphorsulfonic acid (CSA, 530 mg, 2.28 mmol, 0.1 eq). The reaction mixture was stirred at room temperature until TLC analysis (8:2 CHCl₃-MeOH, 4 h) revealed the complete disappearance of the starting material. Et₃N (3 mL) was added, stirring was pursued for 30 min and concentrated under diminished pressure. Purification of the crude product by flash chromatography on silica gel (8:2 CHCl₃-MeOH) gave pure **10** (5.71 g, 91%) as a white foam, *R*_f 0.47 (8:2 CHCl₃-MeOH). Physic-chemical properties and NMR data were in agreement with those reported in the literature [2].

3-azidopropyl 2-acetamido-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside (**13**).

A solution of known **9** [3] (2.96 g, 9.73 mmol) in dry DMF (33 mL) was cooled at 0 °C and treated with freshly distilled 2-methoxypropene (2.8 mL, 29.2 mmol, 3 eq) and camphorsulfonic acid (CSA, 226 mg, .973 mmol, 0.1 eq). The reaction mixture was stirred at room temperature until TLC analysis (8:2 CHCl₃-MeOH, 2 h) revealed the complete disappearance of the starting material. Et₃N (3 mL) was added, stirring was pursued for 30 min and concentrated under diminished pressure. Purification of the crude product by flash chromatography on silica gel (EtOAc + 0.1% Et₃N) gave pure **13** (2.95 g, 88%) as a white foam, *R_f* 0.37 (9:1 CHCl₃-MeOH), [α]_D -46.5 (c 1.11 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 6.61 (d, 1H, *J*_{2,NH} 9.2 Hz, *NH*), 4.40 (d, 1H, *J*_{1,2} 8.3 Hz, H-1), 3.84-3.68 (m, 4H, H-6a, H-6b, CH₂O, OH-3), 3.63 (dd, 1H, *J*_{2,3} 8.7 Hz, *J*_{3,4} 9.5 Hz, H-3), 3.57-3.40 (m, 3H, H-2, H-4, CH₂O), 3.34 (t, 2H, *J*_{vic} 6.7 Hz, CH₂N₃), 3.18 (dt, 1H, *J*_{4,5} 9.8 Hz, *J*_{5,6a} *J*_{5,6b} = 5.6 Hz, H-5), 1.90 (s, 3H, MeCO), 1.76 (m, 2H, CH₂), 1.46, 1.34 (2s, each 3H, CMe₂); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.6 (C=O), 102.6 (C-1), 100.2 (CMe₂), 74.8 (C-4), 73.1 (C-3), 68.1 (C-5), 67.1 (CH₂O), 62.6 (C-6), 57.6 (C-2), 48.8 (CH₂N₃), 29.6 (CH₂), 29.4, 19.4 (CMe₂), 23.3 (MeCO). Anal. Found: C, 48.84; H, 7.05; N, 16.29. Cal for C₁₄H₂₄N₄O₆ (344.37): C, 48.83; H, 7.03; N, 16.27.

Methyl 2-acetamido-3-O-benzoyl-2-deoxy-β-D-glucopyranoside (16)

A solution of known **10** [2] (520 mg, 1.89 mmol) in dry pyridine (6 mL) was cooled to 0°C, treated with BzCl (580 μL, 5.08 mmol, 2.7 eq) and stirred at 0°C until TLC analysis (EtOAc, 2.5 h) revealed the complete disappearance of the starting material and the formation of a faster moving product UV visible (*R_f* 0.56). The mixture was poured into icy water, stirred for 30 min and extracted with CHCl₃ (3×50 mL). The combined extracts were collected, washed with 1M HCl (10 mL) then satd aq NaHCO₃ (10 mL), dried and concentrated under diminished pressure. Purification of the crude product by flash chromatography on silica gel (25:75 hexane-EtOAc + 0.1% Et₃N) gave pure methyl 2-acetamido-3-O-benzoyl-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside (**11**) (631 mg, 88%) as a white foam, *R_f* 0.23 (25:75 hexane-EtOAc), [α]_D -27.5 (c 1.1 in CHCl₃); ¹H NMR (250.13 MHz, CD₃CN): δ 7.98 (m, 2H, Ar-*H*), 7.63 (m, 1H, Ar-*H*), 7.48 (m, 2H, Ar-*H*), 6.56 (d, 1H, *J*_{2,NH} 9.7 Hz, *NH*), 5.27 (dd, 1H, *J*_{2,3} 10.2 Hz, *J*_{3,4} 9.4 Hz, H-3), 4.56 (d, 1H, *J*_{1,2} 8.5 Hz, H-1), 4.01 (dd, 1H, H-2), 3.96 (dd, 1H, *J*_{4,5} 9.7 Hz, H-4), 3.95-3.79 (m, 2H, H-6a, H-6b), 3.42 (m, 1H, H-5), 3.42 (s, 3H, OMe), 1.70 (s, 3H, MeCO), 1.44-1.27 (2s, each 3H, CMe₂); ¹³C NMR (62.9 MHz, CD₃CN): δ 170.8

(CONH), 166.8 (PhCO), 134.3-129.5 (Ar-CH), 130.8 (Ar-C), 103.3 (C-1), 100.4 (CMe₂), 74.1 (C-3), 72.7 (C-4), 67.9 (C-5), 62.6 (C-6), 57.3 (OMe), 55.2 (C-2), 29.3, 19.4 (CMe₂) 23.0 (MeCO). Anal. Found: C, 60.18; H, 6.67; N, 3.72. Calc for C₁₉H₂₅NO₇ (379.41): C, 60.15; H, 6.64; N, 3.69.

Hydrolysis of **11** (202 mg, 0.533 mmol) performed according to the general procedure A. The crude product was purified by flash chromatography (EtOAc + 0.1% Et₃N) to give pure the known diol **16** (174 mg, 96%) as a white solid, *R*_f 0.22 (9:1 CHCl₃-MeOH). Physic-chemical properties and NMR data were in agreement with those reported in the literature [4].

Methyl 2-acetamido-3-O-benzyl-2-deoxy-β-D-glucopyranoside (17)

Compound **10** (6.30 g, 22.9 mmol) was dissolved in THF-H₂O (99.5:0.5, 150 mL). Powdered KOH (5.10 g, 91.2 mmol, 4 eq) and 18-crown-6 (150 mg, 0.57 mmol, 0.025 eq) were added, and the resulting mixture was vigorously stirred at room temperature for 30 min at 0°C. Benzyl bromide (5.24 mL, 45.62 mmol, 2 eq) was added, and the reacting mixture was stirred at room temperature until TLC analysis (EtOAc, 4 h) revealed the complete disappearance of the starting material and the formation of a major faster-moving product (*R*_f 0.41). MeOH (2 mL) was added, the mixture was stirred for an additional 10 min, solvents were evaporated under diminished pressure and the residue was portioned between CH₂Cl₂ (40 mL) and H₂O (40 mL). The aqueous phase was extracted with CH₂Cl₂ (3×40 mL) and the collected organic layers were dried, filtered and concentrated under diminished pressure. Purification of the crude product by flash chromatography on silica gel (4:6 hexane-EtOAc + 0.1% Et₃N) gave pure methyl 2-acetamido-3-O-benzyl-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside (**12**) (6.53 g, 78%) as a white solid, *R*_f 0.41 (EtOAc), [α]_D +22.6 (*c* 1.1 in CHCl₃), mp 172-174 °C (from EtOAc-hexane), ¹H NMR (250.13 MHz, CD₃CN): δ 7.39-7.22 (m, 5H, Ar-*H*), 6.63 (d, 1H, *J*_{2,NH} 8.2 Hz, NH), 4.73, 4.56 (AB system, 2H, *J*_{A,B} 11.7 Hz, CH₂Ph), 4.35 (d, 1H, *J*_{1,2} 8.5 Hz, H-1), 3.85 (dd, 1H, *J*_{6a,6b} 10.2 Hz, *J*_{5,6b} 5.6, H-6b), 3.76 (dd, 1H, *J*_{5,6a}=*J*_{5,6b} 5.6 Hz, H-6a), 3.75 (m, 2H, H-2, H-4), 3.49 (dd, 1H, *J*_{2,3} 8.9 Hz, *J*_{3,4} 10 Hz, H-3), 3.37 (s, 3H, OMe), 3.22 (dt, 1H, *J*_{4,5} 10.9 Hz, H-5), 1.85 (s, 3H, MeCON), 1.49, 1.37 (2s, each 3H, CMe₂); ¹³C NMR (62.9 MHz, CD₃CN): δ 170.9 (C=O), 139.9 (Ar-C), 129.1, 128.6, 128.3 (Ar-CH), 103.7 (C-1), 100.1 (CMe₂), 80.0 (C-3), 75.3 (C-4), 74.2 (CH₂Ph), 67.7 (C-5), 62.7 (C-6), 57.1 (OMe), 55.5 (C-2), 29.5, 19.5 (CMe₂), 23.3

(MeCON). Anal. Found: C, 62.41; H, 7.43; N, 3.80. Calc for C₁₉H₂₇NO₆ (365.43): C, 62.45; H, 7.45; N, 3.83.

Hydrolysis of **12** (3.97 g, 10.86 mmol) performed according to the general procedure A. The crude product was purified by flash chromatography (EtOAc + 0.1% Et₃N) to give pure the known diol **17** (3.39 g, 96%) as a white solid, *R*_f 0.18 (9:1 CHCl₃- MeOH), mp 205-209 °C (from EtOAc), [α]_D -25.9 (c 1.1 in CHCl₃), Lit [5] [α]_D -26.6 (c 0.74 in CH₃OH). NMR data were in agreement with those reported in the literature [5].

3-Azidopropyl 2-acetamido-3-O-benzoyl-2-deoxy-β-D-glucopyranoside (**18**)

A solution of **13** (412 mg, 1.20 mmol) in dry pyridine (4.5 mL) was cooled to 0°C, treated with BzCl (0.43 mL, 3.71 mmol, 3.1 eq) and stirred at 0°C until TLC analysis (EtOAc, 2.5 h) revealed the complete disappearance of the starting material and the formation of a faster moving product UV visible (*R*_f 0.62). The mixture was poured into icy water, stirred for 15 min and extracted with CHCl₃ (3×10 mL). The combined extracts were collected, washed with 1M HCl (5 mL) then satd aq NaHCO₃ (5 mL), dried and concentrated under diminished pressure. The crude residue (520 mg, 97%) was constituted (NMR) exclusively by a 3-azidopropyl 2-acetamido-3-O-benzoyl-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside (**14**) as a white foam, *R*_f 0.27 (1:1 hexane-EtOAc), ¹³C NMR (62.9 MHz, CDCl₃): δ 170.4 (MeCO), 167.0 (PhCO), 133.4, 129.7, 128.4 (Ar-CH), 129.0 (Ar-C), 102.0 (C-1), 99.6 (CMe₂), 73.3 (C-3), 71.7 (C-4), 66.7 (C-5), 66.0 (CH₂O), 61.8 (C-6), 53.6 (C-2), 47.7 (CH₂N₃), 28.7 (CH₂), 28.6, 18.7 (Me₂C), 23.0 (MeCON). Hydrolysis of crude **14** (493 mg, 1.10 mmol) performed according to the general procedure A. The crude product was purified by flash chromatography (EtOAc + 0.1% Et₃N) to give pure the diol **18** (413 mg, 89% calculated from **13**) as a white foam, *R*_f 0.29 (EtOAc), [α]_D -3.54 (c 1.0 in MeOH); ¹H NMR (250.13 MHz, CD₃CN): δ 8.01 (m, 2H, Ar-*H*), 7.61 (m, 1H, Ar-*H*), 7.48 (m, 2H, Ar-*H*), 6.98 (d, 1H, *J*_{2,NH} 8.5 Hz, NH), 5.23 (dd, 1H, *J*_{2,3} 9.4 Hz, H-3), 4.62 (d, 1H, *J*_{1,2} 8.5 Hz, H-1), 4.38 (bt, 1H, OH-6), 3.96 (dd, 1H, H-2), 3.90-3.51 (m, 6H, H-4, H-6a, H-6b, OH-4, CH₂O), 3.45 (ddd, 1H, *J*_{4,5} 10.3 Hz, *J*_{5,6a} 2.6 Hz, *J*_{5,6b} 6.8 Hz, H-5), 4.38 (bt, 1H, OH-6), 3.35 (t, 2H, *J*_{vic} 6.8 Hz, CH₂N₃), 1.79 (m, 2H, CH₂), 1.70 (s, 3H, MeCO); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.3 (MeCO), 167.2 (PhCO), 134.1, 130.4, 129.4 (ArCH), 130.9 (Ar-C), 101.6 (C-1), 77.5 (C-3), 77.0 (C-5), 69.5 (C-4), 66.9 (CH₂O), 62.3 (C-6), 54.7 (C-2),

48.8 (CH₂N₃), 29.5 (CH₂), 23.0 (MeCON). Anal. Found: C, 52.97; H, 5.95; N, 13.75. Calc for C₁₈H₂₄N₄O₇ (408.41): C, 52.94; H, 5.92; N, 13.72.

3-Azidopropyl 2-acetamido-3-O-benzyl-2-deoxy-β-D-glucopyranoside (**19**)

Compound **13** (300 mg, 0.87 mmol) was dissolved in THF-H₂O (99.5:0.5, 6.0 mL). Powdered KOH (195 mg, 3.49 mmol, 4 eq) and 18-crown-6 (5.75 mg, 0.022 mmol, 0.025 eq) were added, and the resulting mixture was vigorously stirred at room temperature for 30 min at 0°C. Benzyl bromide (0.21 mL, 1.74 mmol, 2 eq) was added, and the reacting mixture was stirred at room temperature until TLC analysis (EtOAc, 4 h) revealed the complete disappearance of the starting material and the formation of a major faster-moving product (*R*_f 0.57). MeOH (1 mL) was added, the mixture was stirred for an additional 10 min, solvents were evaporated under diminished pressure and the residue was portioned between CH₂Cl₂ (20 mL) and H₂O (20 mL). The aqueous phase was extracted with CH₂Cl₂ (4×20 mL) and the collected organic layers were dried, filtered and concentrated under diminished pressure. The crude residue (359 mg, 95%) was constituted (NMR) exclusively by a 3-azidopropyl 2-acetamido-3-O-benzyl-2-deoxy-4,6-O-isopropylidene-β-D-glucopyranoside (**15**) as a white solid, *R*_f 0.23 (1:1 hexane-EtOAc), δ ¹³C NMR (62.9 MHz, CD₃CN): δ 170.7 (C=O), 140.1 (Ar-C), 129.1-128.3 (Ar-CH), 102.9 (C-1), 100.1 (CMe₂), 79.9 (C-3), 75.3 (C-4), 74.2 (CH₂Ph), 67.8 (C-5), 67.0 (CH₂O), 62.8 (C-6), 55.7 (C-2), 48.7 (CH₂N₃), 29.5 (CH₂), 29.3, 19.5 (Me₂C), 23.3 (MeCO).

Hydrolysis of crude **15** (359 mg, 0.826 mmol) performed according to the general procedure A. The crude product was purified by flash chromatography (EtOAc + 0.1% Et₃N) to give pure the diol **19** (313 mg, 91% calculated from **13**) as a white solid, *R*_f 0.15 (EtOAc), mp 156-158 °C (from EtOAc), [α]_D +1.68 (c 0.95 in MeOH), ¹H NMR (250.13 MHz, CD₃CN): δ 7.34-7.28 (m, 5H, Ar-*H*), 6.60 (d, 1H, *J*_{2,NH} 9.1 Hz, *NH*), 4.79, 4.63 (AB system, 2H, *J*_{A,B} 11.3 Hz, CH₂Ph), 4.40 (d, 1H, *J*_{1,2} 8.4 Hz, H-1), 3.84 (dt, 1H, *J*_{vic} 5.8 Hz, *J*_{gem} 10.2 Hz, CH₂O), 3.75-3.60 (m, 4H, H-2, H-6a, H-6b, OH-4), 3.53 (dt, 1H, *J*_{vic} 6.3 Hz, *J*_{gem} 10.2 Hz, CH₂O), 3.45 (m, 2H, H-3, H-4), 3.28 (ddd, 1H, *J*_{4,5} 9.3 Hz, *J*_{5,6a} 3.0 Hz, *J*_{5,6b} 5.5 Hz, H-5), 3.35 (t, 2H, *J*_{vic} 6.8 Hz, CH₂N₃), 3.00 (bt, 1H, OH-6), 1.84 (s, 3H, MeCO), 1.77 (m, 2H, CH₂); ¹³C NMR (62.9 MHz, CD₃CN): δ 170.9 (C=O), 140.1 (Ar-C), 129.1, 128.8, 128.3 (Ar-CH), 102.2 (C-1), 83.4 (C-3), 77.0 (C-5), 74.9 (CH₂Ph), 71.9 (C-4), 66.7 (CH₂O), 62.7 (C-6), 55.5 (C-2), 48.8 (CH₂N₃), 29.6 (CH₂), 23.3 (MeCON). Anal.

Found: C, 54.85; H, 6.67; N, 14.24. Calc for C₁₈H₂₆N₄O₆ (394.43): C, 54.81; H, 6.64; N, 14.20.

Methyl 2-acetamido-3-O-benzoyl-6-O-tert-butyldimethylsilyl-2-deoxy-β-D-glucopyranoside (20)

Silylation of **16** (159 mg, 0.468 mmol) performed according to the general procedure B. The crude product was purified by flash chromatography (35:65 hexane-EtOAc + 0.1 % Et₃N) to give pure the acceptor **20** (172 mg, 81%) as a white solid, *R*_f 0.70 (9:1 CHCl₃-MeOH), mp 165-172 °C (from EtOAc-hexane), [α]_D -18.8 (c 1.0 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 8.00 (m, 2H, Ar-*H*), 7.61 (m, 1H, Ar-*H*), 7.49 (m, 2H, Ar-*H*), 6.58 (d, 1H, *J*_{2,NH} 9.6 Hz, NH), 5.17 (dd, 1H, *J*_{2,3} 10.6 Hz, *J*_{3,4} 9.0 Hz, H-3), 4.48 (d, 1H, *J*_{1,2} 8.5 Hz, H-1), 3.94 (dd, 1H, *J*_{5,6b} 2.5 Hz, *J*_{6a,6b} 11.3 Hz, H-6b), 3.90 (dd, 1H, *J*_{5,6a} 4.7 Hz, H-6a), 3.89 (m, 1H, H-2), 3.82 (d, 1H, *J*_{4,OH} 5.2 Hz, OH-4), 3.70 (ddd, 1H, *J*_{4,5} 9.7 Hz, H-4), 3.43 (ds, 3H, OMe), 3.42 (ddd, 1H, H-5), 1.67 (s, 3H, MeCO), 0.92 (s, 9H, SiCMe₃), 0.11, 0.10 (2s, each 3H, Me₂Si); ¹³C NMR (62.9 MHz, CD₃CN): δ 170.8 (MeCO), 167.2 (PhCO), 134.1, 130.4, 129.4 (Ar-CH), 131.1 (Ar-C), 102.5 (C-1), 77.8 (C-3), 77.1 (C-5), 69.4 (C-4), 63.5 (C-6), 56.9 (OMe), 54.6 (C-2), 26.2 (CMe₂), 23.0 (MeCO), 19.0 (SiCMe₃), -5.02, -5.12 (Me₂Si). Anal. Found: C, 58.28; H, 7.81; N, 3.12. Calc for C₂₂H₃₅NO₇Si (453.61): C, 58.25; H, 7.78; N, 3.09.

Methyl 2-acetamido-3-O-benzyl-6-O-tert-butyldimethylsilyl-2-deoxy-β-D-glucopyranoside (21)

Silylation of **17** (3.38 g, 10.4 mmol) performed according to the general procedure B. The crude product was purified by flash chromatography (1:9 hexane- EtOAc + 0.1 % Et₃N) to give pure the acceptor **21** (4.24 g, 93%) as a white solid, *R*_f 0.52 (EtOAc), [α]_D +1.01 (c 1.0 in CHCl₃); ¹H NMR (250.13 MHz, CD₃CN): δ 7.35-7.20 (m, 5H, Ar-*H*), 6.69 (d, 1H, *J*_{2,NH} 9.4 Hz, NH), 4.79, 4.62 (AB system, *J*_{AB} 11.3 Hz, CH₂Ph), 4.28 (d, 1H, *J*_{1,2} 8.4 Hz, H-1), 3.91 (dd, 1H, *J*_{6a,6b} 11.3 Hz, *J*_{5,6b} 2.6 Hz, H-6b), 3.79-3.63 (m, 1H, H-2, H-6a, OH-4), 3.50-3.40 (m, 2H, H-3, H-4), 3.38 (s, 3H, OMe), 3.22 (ddd, 1H, *J*_{4,5} 9.4 Hz, *J*_{5,6a} 4.6 Hz, H-5), 1.83 (s, 3H, CH₃CON), 0.90 (s, 9H, CMe₃), 0.088, 0.086 (2s, each 3H, Me₂Si); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.0 (C=O), 140.2 (Ar-C), 129.1, 128.7, 128.3 (Ar-CH), 102.9 (C-1), 83.7 (C-3), 77.1 (C-5), 74.9 (CH₂Ph), 71.6 (C-4), 63.8 (C-6), 56.7 (OMe), 55.3 (C-2), 26.2 (CMe₃), 23.4 (MeCON), 18.9 (SiCMe₃), -5.06, -5.13

(Me_2Si). Anal. Found: C, 60.14; H, 8.45; N, 3.22. Calc for $\text{C}_{22}\text{H}_{37}\text{NO}_6\text{Si}$ (439.62): C, 60.11; H, 8.48; N, 3.19.

3-Azidopropyl 2-acetamido-3-O-benzoyl-6-O-*tert*-butyldimethylsilyl-2-deoxy- β -D-glucopyranoside (22)

Silylation of **18** (1.54 g, 3.77 mmol) performed according to the general procedure B. The crude product was purified by flash chromatography (1:1 hexane-EtOAc + 0.1 % Et_3N) to give the acceptor pure **22** (1.80 g, 91%) as a white foam, R_f 0.76 (EtOAc), $[\alpha]_D -11.2$ (c 1.0 in CHCl_3), ^1H NMR (250.13 MHz, CD_3CN): δ 8.03-7.98 (m, 2H, Ar-*H*), 7.65-7.58 (m, 1H, Ar-*H*), 7.52-7.45 (m, 2H, Ar-*H*), 6.73 (d, 1H, $J_{2,\text{NH}}$ 9.6 Hz, NH), 5.19 (dd, 1H, $J_{2,3}$ 10.6 Hz, $J_{3,4}$ 9.0 Hz, H-3), 4.57 (d, 1H, $J_{1,2}$ 8.5 Hz, H-1), 3.98-3.78 (m, 5H, H-2, H-6a, H-6b, OH, CH_2O), 3.69 (bt, 1H, $J_{4,5}$ 9.5 Hz, H-4), 3.43 (ddd, 1H, $J_{5,6a}$ 2.4 Hz, $J_{5,6b}$ 4.3 Hz, H-5), 3.57 (dt, 1H, J_{vic} 6.2 Hz, J_{gem} 10.2 Hz, CH_2O), 3.35 (t, 2H, J_{vic} 6.8 Hz, CH_2N_3), 1.79 (m, 2H, CH_2), 1.69 (s, 3H, MeCO), 0.92 (s, 9H, CMe_3), 0.10, 0.09 (2s, each 3H, Me_2Si); ^{13}C NMR (62.9 MHz, CD_3CN): δ 171.0 (MeCO), 167.2 (PhCO), 134.1, 130.4, 129.4 (ArCH), 131.0 (Ar-C), 101.6 (C-1), 77.6 (C-3), 77.1 (C-5), 69.4 (C-4), 66.9 (CH_2O), 63.5 (C-6), 54.7 (C-2), 48.8 (CH_2N_3), 29.5 (CH_2), 26.2 (CMe_3), 23.0 (MeCON), 18.9 (CMe_3), -5.02, -5.09 (Me_2Si). Anal. Found: C, 55.19; H, 7.36; N, 10.76. Calc for $\text{C}_{24}\text{H}_{38}\text{N}_4\text{O}_7\text{Si}$ (522.67): C, 55.15; H, 7.33; N, 10.72.

3-Azidopropyl 2-acetamido-3-O-benzyl-6-O-*tert*-butyldimethylsilyl-2-deoxy- β -D-glucopyranoside (23)

Silylation of **19** (925 mg, 2.34 mmol) performed according to the general procedure B. The crude product was purified by flash chromatography (1:1 hexane- EtOAc + 0.1 % Et_3N) to give pure the acceptor **23** (1.14 g, 96%) as a white foam, R_f 0.25 (1:1 hexane-EtOAc), $[\alpha]_D +11.2$ (c 1.3 in CHCl_3), ^1H NMR (250.13 MHz, CD_3CN): δ 7.34-7.24 (m, 5H, Ar-*H*), 6.73 (m, 1H, NH), 4.80, 4.64 (AB system, 2H, $J_{A,B}$ 11.3 Hz, CH_2Ph), 4.37 (d, 1H, $J_{1,2}$ 8.4 Hz, H-1), 3.90 (dd, 1H, $J_{6a,6b}$ 11.0 Hz, $J_{5,6b}$ 4.1 Hz, H-6b), 3.85-3.63 (m, 4H, H-2, H-6a, OH-4, CH_2O), 3.54-3.45 (m, 3H, H-3, H-4, CH_2O), 3.33 (t, 2H, J_{vic} 6.8 Hz, CH_2N_3), 3.26 (ddd, 1H, $J_{4,5}$ 9.4 Hz, $J_{5,6a}$ 5.3 Hz, H-5), 1.86 (s, 3H, MeCO), 1.76 (m, 2H, CH_2), 0.91 (s, 9H, SiCMe_3), 0.093 (s, 6H, Me_2Si); ^{13}C NMR (62.9 MHz, CD_3CN): δ 170.9 (CO), 140.0 (Ar-C), 129.1, 128.7, 128.3 (Ar-CH), 102.1 (C-1), 83.6 (C-3), 77.1 (C-5), 71.6 (C-4), 66.6 (CH_2O), 63.8 (C-6), 55.4 (C-2), 48.8 (CH_2N_3), 29.6 (CH_2), 26.2 (CMe_3), 23.4

(MeCON), 18.9 (CMe₃), -5.03, -5.09 (Me₂Si). Anal. Found: C, 56.71; H, 7.96; N, 11.05. Calc for C₂₄H₄₀N₄O₆Si (508.69): C, 56.67; H, 7.93; N, 11.01.

Experimental procedures and characterization data of 25-28

4-O-[Benzyl 2-O-benzyl-3,4-O-isopropylidene-β-D-galactopyranosyl uronate]-2,3:5,6-di-O-isopropylidene-aldehydo-D-glucose dimethyl acetal (25)

A solution of **24** [6] (700 mg, 1.17 mmol) in acetone (117 mL) was treated with 5% aq. NaHCO₃ (58.45 mL), KBr (278.3, 2.34 mmol, 2 eq) and TEMPO (255.8, 1.64 mmol, 1.4 eq) and the mixture was stirred at 0°C. After 10 min 13% aq. NaOCl (4.9 mL) was added and the mixture was stirred at room temperature until the starting material was completely reacted (15 min, TLC, EtOAc). The reaction mixture was repeatedly co-evaporated with toluene (5×30 mL) under diminished pressure. A solution of the crude product in dry DMF (30.7 mL) KF (680 mg, 11.6 mmol, 10 eq) was added, after 10 min at 0°C was treated with BnBr (497 μL, 5.85 mmol, 5 eq) and the reaction was stirred overnight at room temperature. The suspension was concentrated and the residue was portioned between CH₂Cl₂ (35 mL) and H₂O (35 mL). The reaction was concentrated under diminished pressure and the residue was portioned between CH₂Cl₂ (30 mL) and satd aq NaCl (30 mL). The aqueous phase was extracted with CH₂Cl₂ (3×50 mL) and the collected organic layers were dried over MgSO₄, filtered and concentrated under diminished pressure. Purification of the crude product by flash chromatography on silica gel (7:3 hexane-EtOAc) gave pure **25** (763.5 mg, 93%) as a colorless syrup, *R*_f 0.22 (7:3 hexane-EtOAc), [α]_D -12.0 (*c* 1.16 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 7.39-7.27 (m, 10H, Ar-*H*), 5.28, 5.13 (AB system, 2H, *J*_{A,B} 12.6 Hz, COOCH₂Ph), 4.79, 4.69 (AB system, 2H, *J*_{A,B} 12.0 Hz, OCH₂Ph), 4.68 (d, 1H, *J*_{1',2'} 8.1 Hz, H-1'), 4.52 (m, 2H, H-5', H-2), 4.44 (dd, 1H, *J*_{3',4'} 5.5 Hz, *J*_{4',5'} 2.4 Hz, H-4'), 4.35 (d, 1H, *J*_{1,2} 6.0 Hz, H-1), 4.23 (m, 1H, H-5), 4.20 (dd, 1H, *J*_{2',3'} 7.1 Hz, H-3'), 4.13 (dd, 1H, *J*_{2,3} 7.0 Hz, *J*_{3,4} 1.2 Hz, H-3), 4.05 (dd, 1H, *J*_{5,6b} 5.9 Hz, *J*_{6a,6b} 8.7 Hz, H-6b), 3.94 (dd, 1H, *J*_{5,6a} 6.4 Hz, H-6a), 3.82 (dd, 1H, *J*_{4,5} 6.1 Hz, H-4), 3.34, 3.33 (2s, each 3H, OMe), 3.31 (dd, 1H, H-2'), 1.39, 1.30 (2s, each 3H, CMe₂), 1.27, 1.34 (2s, each 6H, 2×CMe₂); ¹³C NMR (62.9 MHz, CD₃CN): δ 167.7 (C-6'), 139.4, 136.9 (2×Ar-C), 129.4-128.4 (Ar-CH), 110.9, 110.6, 109.2 (3×CMe₂), 106.1 (C-1), 103.1 (C-1'), 80.6 (C-2'), 79.6 (C-3'), 78.3 (C-3), 77.8 (C-4), 77.5 (C-5), 76.4 (C-2), 75.1 (C-4'), 74.2 (OCH₂Ph), 72.5 (C-5'), 67.1 (COOCH₂Ph),

66.5 (C-6), 55.8, 54.5 (2×OMe), 28.0, 27.7, 27.3, 26.9, 26.4, 25.5 (3×Me₂C). Anal Found: C, 63.26; H, 7.19. Calc for C₃₇H₅₀O₁₃ (702.79): C, 63.23; H, 7.17.

4-O-[Benzyl 2-O-benzyl-3,4-di-O-acetyl-β-D-galactopyranosyl uronate]-1,2,3,6-tetra-O-acetyl-α,β-D-glucopyranoside (26)

A solution of protected disaccharide **25** (810.4 mg, 1.153 mmol) in 80% aq AcOH (4 mL) was stirred at 80 °C until the starting material was completely reacted (TLC, 9:1 CHCl₃-MeOH, 4 h) with formation of a slower moving product. The solution was concentrated under diminished pressure by co-evaporation with toluene (4×30 mL), a mixture of 1:2 Ac₂O-Py was added, the solution was stirred overnight at room temperature and was concentrated under diminished pressure by co-evaporation with toluene (4×35 mL). Flash chromatographic purification on silica gel, eluting with 6:4 hexane- EtOAc, afforded pure **26** (808 mg, 89%) as an 1:1 α/β anomeric mixture, as established on the basis of the integration of the H-1 signals (¹H NMR), a white foam, *R*_f 0.76 (6:4 hexane-EtOAc), ¹H NMR (250.13 MHz, CD₃CN) of α-**26**: δ 6.18 (d, 1H, *J*_{1,2} 3.8 Hz, H-1); β-**26**: δ 5.81 (d, 1H, *J*_{1,2} 8.3 Hz, H-1); cluster of signals for both anomers: δ 7.44-7.21 (m, 10H, Ar-*H*), 5.53 (m, 1H, H-4'), 5.40 (m, 1H, H-3), 5.12, 5.07 (AB system, 2H, *J*_{A,B} 12.1 Hz, COOCH₂Ph), 4.92 (m, 2H, H-2, H-3'), 4.73, 4.71, 4.58, 4.56 (2×AB systems, each 2H, *J*_{A,B} 11.2, *J*_{A,B} 11.5 Hz, CH₂Ph), 4.52-4.45 (m, 2H, H-1', H-5'), 4.40-4.31 (m, 2H, H-6a, H-6b), 4.12-3.95 (m, 2H, H-5, H-4), 3.46 (m, 1H, H-2'), 2.18, 2.12, 2.09, 2.06, 2.02 (5s, each 3H, 5×MeCO), 2.00, 1.98 (2s, each 6H, 4×MeCO), 1.89 (m, 9H, 3×MeCO); ¹³C NMR (62.9 MHz, CD₃CN): of α-**26**: δ 89.5 (C-1); β-**26**: δ 92.2 (C-1); cluster of signals for both anomers: δ 171.4-170.0 (C=O), 167.9 (C-6'), 139.0, 138.9, 136.4 (Ar-C), 129.5-128.7 (Ar-CH), 103.4, 103.2 (C-1'), 77.4, 77.3 (C-2'), 76.6, 76.4 (C-4), 75.9 (CH₂Ph), 74.4, 71.8 (C-5), 72.9 (C-5'), 72.6 (C-3'), 72.5, 69.9 (C-3), 71.0, 70.2 (C-2), 69.5 (C-4'), 67.9 (COOCH₂Ph), 62.5, 62.2 (C-6), 21.1-20.5 (MeCO).

4-O-[Benzyl 2-O-benzyl-3,4-di-O-acetyl-β-D-galactopyranosyl uronate]-2,3,6-tri-O-acetyl-α,β-D-glucopyranose (27)

A solution of **26** in dry DMF (804.5 mg, 1.02 mmol) was treated with NH₂NH₂·AcOH (110.6 mg, 1.23 mmol, 1.2 eq) and the mixture was stirred at 60°C until the starting material was completely disappeared (TLC, 2:8 hexane-EtOAc, 30 min). The reaction was concentrated under diminished pressure and the residue was portioned between

CH₂Cl₂ (30 mL) and satd aq NaCl (30 mL). The aqueous phase was extracted with CH₂Cl₂ (3×50 mL) and the collected organic layers were dried over MgSO₄, filtered and concentrated under diminished pressure. Purification of the crude product by flash chromatography on silica gel (7:3 hexane-EtOAc) gave pure **27** (602 mg, 79%) as an 7:3 α/β anomeric mixture, as established on the basis of the integration of the C1 signals (¹³C NMR), as a white foam, *R*_f 0.22 (1:1 hexane-EtOAc); ¹H NMR (250.13 MHz, CD₃CN): of α -**27**: δ 5.42 (dd, 1H, *J*_{2,3} 9.3 Hz, *J*_{3,4} 10.4 Hz, H-3), 5.23 (m, 1H, H-1), 3.44 (d, 1H, *J*_{2',3'} 10.0 Hz, H-2'), 2.08, 2.02, 1.98, 1.86, 1.85 (5s, each 3H, 5×MeCO); β -**27**: δ 3.42 (d, 1H, *J*_{2',3'} 9.9 Hz, H-2'), 2.06, 2.01, 1.99, 1.97, 1.87 (5s, each 3H, 5×MeCO); cluster of signals for both anomers: δ 7.37-7.24 (m, 10H, Ar-*H*), 5.47 (d, 1H, *J*_{4',5'} 1.6 Hz, *J*_{3',4'} 3.7 Hz, H-4'), 5.16, 5.08 (AB system, 2H, *J*_{A,B} 12.1 Hz, COOCH₂Ph), 5.00 (d, 1H, H-3'), 4.78-4.68 (m, 3H, β -H-1, β -H-3, α,β -H-2), 4.73, 4.55 (AB system, 2H, *J*_{A,B} 11.5, CH₂Ph), 4.48 (d, 1H, H-5'), 4.46 (m, 1H, H-1'), 4.38-4.11 (m, 3H, H-5, H-6a, H-6b), 3.92-3.79 (m, 1H, H-4); ¹³C NMR (62.9 MHz, CD₃CN): of α -**27**: δ 103.4 (C-1'), 90.4 (C-1), 77.4 (C-4), 69.2 (C-5), 72.0, (C-2), 70.0 (C-3); β -**27**: δ 103.3 (C-1'), 95.2 (C-1), 77.1 (C-4), 73.6, 73.4, 73.0 (C-2, C-3, C-4); cluster of signals for both anomers: δ 171.5-170.6 (C=O), 167.1 (C-6'), 139.0, 136.4 (Ar-C), 129.5-128.7 (Ar-CH), 77.3 (C-2'), 75.9 (CH₂Ph), 72.9 (C-5'), 72.6 (C-3'), 69.6 (C-4'), 67.9 (COOCH₂Ph), 62.9 (C-6), 21.1-20.6 (MeCO).

4-O-[Benzyl 2-O-benzyl-3,4-di-O-acetyl- β -D-galactopyranosyl uronate]-2,3,6-tri-O-acetyl- α -D-glucopyranosyl trichloroacetimidate (28**)**

A solution of **27** (350 mg, 0.469 mmol) in dry CH₂Cl₂ (2.20 mL) was cooled at 0 °C and a large excess of CCl₃CN (282 mL, 2.81 mmol, 6 eq) and a catalytic amount of DBU (0.054 eq) were added. The reaction mixture was stirred at room temperature until TLC analysis (1:1 hexane-EtOAc, 30 min) showed the disappearance of the starting product and then was concentrated under diminished pressure. Purification of the crude by flash chromatography on silica gel (6:4 hexane-EtOAc) gave pure the donor **28** (380 mg, 91%) as a white foam, *R*_f 0.25 (6:4 hexane-EtOAc), [α]_D +59.6 (c 1.14 in CHCl₃), ¹H NMR (250.13 MHz, CDCl₃): δ 8.63 (s, 1H, NH), 7.34-7.15 (m, 10H, Ar-*H*), 6.46 (d, 1H, *J*_{1,2} 3.7 Hz, H-1), 5.58 (dd, 1H, *J*_{4',5'} 1.4 Hz, *J*_{3',4'} 3.5 Hz, H-4'), 5.60 (dd, 1H, *J*_{2,3} 10.3 Hz, *J*_{3,4} 9.1 Hz, H-3), 5.13, 5.04 (AB system, 2H, *J*_{A,B} 11.9 Hz, COOCH₂Ph), 5.04 (dd, 1H, H-2), 4.92 (dd, 1H, *J*_{2',3'} 10.2 Hz, H-3'), 4.67, 4.57 (AB system, 2H, *J*_{A,B} 11.6, CH₂Ph),

4.40 (dd, 1H, $J_{6a,6b}$ 12.3 Hz, $J_{5,6b}$ 1.9 Hz, H-6b), 4.39 (dd, 1H, $J_{1',2'}$ 7.6 Hz, H-1'), 4.19 (d, 1H, H-5'), 4.13 (dd, 1H, H-6a), 4.07 (ddd, 1H, $J_{4,5}$ 10.1 Hz, $J_{5,6a}$ 3.7 Hz, H-5), 3.54 (dd, 1H, H-2'), 2.14, 1.99, 1.98, 1.85, 1.82 (5s, each 3H, 5×MeCO); ^{13}C NMR (62.9 MHz, CDCl_3): δ 170.7, 170.0, 169.9, 169.8, 169.5 (5×C=O), 165.4 (C-6'), 160.7 (C=NH), 137.7, 134.7 (2×Ar-C), 128.9-127.5 (Ar-CH), 102.5 (C-1'), 92.9 (C-1), 90.7 (CCl_3), 76.4 (C-2'), 75.3 (CH_2Ph), 75.1 (C-4), 72.1 (C-5'), 71.9 (C-3'), 71.3 (C-5), 69.8, (C-2), 68.9 (C-3), 68.4 (C-4'), 67.3 (COOCH_2Ph), 61.0 (C-6), 20.8-20.2 (5×MeCO). Anal. Found: C, 51.25; H, 4.78; N, 1.59. Calc for $\text{C}_{38}\text{H}_{42}\text{Cl}_3\text{NO}_{17}$ (891.10): C, 51.22; H, 4.75; N, 1.57.

Experimental procedures and characterization data of 31-40

General procedure A for the 4-O-glycosylation. A mixture of the appropriate acceptors **20-23** (1.0 eq), excess of opportune donors **39,30** (1.5 eq) and activated AW-300 MS (800 mg) in dry CH_2Cl_2 (17 mL), was stirred for 30 min at room temperature. The suspension was then cooled to $-30\text{ }^\circ\text{C}$ and a solution of TMSOTf (0.5 eq) in dry CH_2Cl_2 was added. The reaction mixture was allowed to slowly attain room temperature with stirring until the appropriate acceptor was disappeared (17-24 h, TLC) and the formation of a higher major UV visible spot. Et_3N (0.5 mL) was added and after 30 min the mixture was filtered through a short pad of Celite, diluted with CH_2Cl_2 and concentrated under diminished pressure. Purification of crude product by flash chromatography on silica gel afforded pure the disaccharide **31-35**.

Methyl 4-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-2-acetamido-3-O-benzoyl-6-O-*t*-butyldimethylsilyl-2-deoxy- β -D-glucopyranoside (**31**).

A solution of acceptor **20** (161 mg, 0.355 mmol, 1 eq) and donor **29** (262 mg, 0.532 mmol, 1.5 eq) in dry CH_2Cl_2 (5.5 mL) was treatment with TMSOTf (32 μL , 0.177 mmol, 0.5 eq) in dry CH_2Cl_2 (0.5 mL) in accordance with the general procedure A. The reaction was stirred until the acceptor was disappeared (12 h, TLC,). Purification of the crude product by flash chromatography on silica gel (3:7 hexane-EtOAc + 0.1% Et_3N) gave pure disaccharide **31** (173 mg, 62%) as a white foam, R_f 0.23 (3:7 hexane-EtOAc), $[\alpha]_D -11.95$ (c 0.94 in CHCl_3), ^1H NMR (250.13 MHz, $\text{CD}_3\text{CN-CDCl}_3$): δ 8.01-7.98 (m, 2H, Ar-*H*), 7.61-7.54 (m, 1H, Ar-*H*), 7.49-7.41 (m, 2H, Ar-*H*), 6.48 (d, 1H, $J_{2,\text{NH}}$ 9.5 Hz, NH), 5.24 (dd, 1H, $J_{2,3}$ 10.5 Hz, $J_{3,4}$ 9.2 Hz, H-3), 5.11 (dd, 1H, $J_{3',4'}$ 3.1 Hz, $J_{4',5'}$ 1.1 Hz, H-4'), 4.86 (dd, 1H, $J_{2',3'}$ 10.3 Hz, H-3'), 4.82 (dd, 1H, $J_{1',2'}$ 7.3 Hz, H-2'), 4.67 (d,

1H, H-1'), 4.47 (d, 1H, $J_{1,2}$ 8.5, H-1), 4.10-3.98 (m, 2H, H-4, H-6b), 3.95-3.83 (m, 2H, H-2, H-6a), 3.69 (dt, 1H, $J_{5',6'a}=J_{5',6'b}$ 6.5 Hz, H-5'), 3.52 (dd, 1H, $J_{6'a,6'b}$ 11.2 Hz, H-6'b), 3.44 (m, 1H, H-5), 3.42 (s, 3H, OMe), 3.37 (dd, 1H, H-6'a), 2.01, 1.94, 1.86, 1.86 (4s, each 3H, 4×MeCOO), 1.72 (s, 3H, MeCON), 0.94 (s, 9H, Me₃C), 0.13, 0.12 (2s, each 3H, Me₂Si); ¹³C NMR (62.9 MHz, CD₃CN-CDCl₃): δ 170.7-170.2 (C=O), 166.5 (PhCO), 133.9, 130.3, 129.2 (Ar-CH), 131.2 (Ar-C), 102.3 (C-1), 100.7 (C-1'), 75.8 (C-5), 75.5 (C-4), 74.4 (C-3), 71.5 (C-3'), 71.3 (C-5'), 69.9 (C-2'), 67.8 (C-4'), 61.9 (C-6), 61.5 (C-6'), 56.8 (OMe), 54.5 (C-2), 26.2 (Me₃C), 23.3 (MeCON), 21.1-20.7 (4×MeCOO), 18.8 (Me₃C), -4.86, -5.09 (Me₂Si). Anal. Found: C, 55.18; H, 6.86; N, 1.82. Calc for C₃₆H₅₃NO₁₆Si (783.90): C, 55.16; H, 6.82; N, 1.79.

Methyl 4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-acetamido-3-O-benzyl-6-O-*t*-butyldimethylsilyl-2-deoxy-β-D-glucopyranoside (32).

A solution of acceptor **21** (773 mg, 1.76 mmol, 1 eq) and donor **29** (1.26 g, 2.56 mmol, 1.5 eq) in dry CH₂Cl₂ (28 mL) was treatment with AW-300 MS (1.45 g) and TMSOTf (154 μL, 0.852 mmol, 0.5 eq) in dry CH₂Cl₂ (1.0 mL) in accordance with the general procedure A. The reaction was stirred until the acceptor was disappeared (12 h, TLC, 3:7 hexane-EtOAc). Purification of the crude product by flash chromatography on silica gel (3:7 hexane-EtOAc) gave pure disaccharide **32** (542 mg, 40%) as a white foam, *R*_f 0.38 (3:7 hexane-EtOAc), [α]_D -8.75 (c 1.12 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 7.38-7.26 (m, 5H, Ar-*H*), 6.55 (d, 1H, $J_{2,NH}$ 9.3 Hz, NH), 5.32 (dd, 1H, $J_{4',5'}$ 0.8 Hz, $J_{3',4'}$ 3.3 Hz, H-4'), 5.09 (dd, 1H, $J_{1',2'}$ 7.5 Hz, $J_{2',3'}$ 10.4 Hz, H-2'), 5.01 (dd, 1H, H-3'), 4.86, 4.57 (AB system, 2H, $J_{A,B}$ 10.7 Hz, CH₂Ph), 4.85 (d, 1H, H-1'), 4.28 (d, 1H, $J_{1,2}$ 8.2 Hz, H-1), 4.03-3.85 (m, 6H, H-5', H-6'a, H-6'b, H-4, H-6a, H-6b), 3.69 (ddd, 1H, $J_{2,3}$ 8.7 Hz, H-2), 3.50 (dd, 1H, $J_{3,4}$ 10.1 Hz, H-3), 3.37 (s, 3H, OMe), 2.09, 2.04, 1.93, 1.91 (4s, each 3H, 4×MeCOO), 1.84 (s, 3H, MeCON), 0.93 (s, 9H, Me₃C), 0.12 (s, 6H, Me₂Si); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.2-170.5 (5×C=O), 140.1 (Ar-C), 128.9-128.3 (Ar-CH), 102.8 (C-1), 100.7 (C-1'), 80.8 (C-3), 76.3 (C-4), 76.2 (C-5), 73.9 (CH₂Ph), 71.7 (C-5'), 71.7 (C-3'), 70.3 (C-2'), 68.3 (C-4'), 62.8 (C-6), 62.3 (C-6'), 56.6 (OMe), 26.3 (Me₃C), 23.3 (MeCON), 21.0-20.1 (4×MeCOO), 18.9 (Me₃C), -4.80, -5.07 (Me₂Si). Anal. Found: C, 56.14; H, 7.18; N, 1.80. Calc for C₃₆H₅₅NO₁₅Si (769.91): C, 56.16; H, 7.20; N, 1.82.

3-Azidopropyl 4-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-2-acetamido-3-O-benzoyl-6-O-*t*-butyldimethylsilyl-2-deoxy- β -D-glucopyranoside (33).

A solution of acceptor **22** (215 mg, 0.41 mmol, 1 eq) and donor **29** (306 mg, 0.62 mmol, 1.5 eq) in dry CH₂Cl₂ (5.5 mL) was treatment with AW-300 MS (350 mg) and TMSOTf (38 μ L, 0.21 mmol, 0.5 eq) in dry CH₂Cl₂ (0.5 mL) in accordance with the general procedure A. The reaction was stirred until the acceptor was disappeared (16 h, TLC, 1:1 hexane-EtOAc). Purification of the crude product by chromatography on silica (first 65:35 hexane-EtOAc + 0.1% Et₃N then 1:1 hexane-EtOAc + 0.1% Et₃N) gave pure disaccharide **33** (165 mg, 47%) as a white foam, *R*_f 0.27 (1:1 toluene-EtOAc), [α]_D -3.28 (c 0.97 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 8.02-7.95 (m, 2H, Ar-*H*), 7.62-7.56 (m, 1H, Ar-*H*), 7.50-7.42 (m, 2H, Ar-*H*), 6.52 (d, 1H, *J*_{2,NH} 9.3 Hz, NH), 5.25 (dd, 1H, *J*_{2,3} 10.5 Hz, *J*_{3,4} 9.6 Hz, H-3), 5.11 (dd, 1H, *J*_{3',4'} 3.1 Hz, *J*_{4',5'} 1.0 Hz, H-4'), 4.90 (dd, 1H, *J*_{2',3'} 10.3 Hz, H-3'), 4.82 (dd, 1H, *J*_{1',2'} 7.5 Hz, H-2'), 4.69 (d, 1H, H-1'), 4.57 (d, 1H, *J*_{1,2} 8.4 Hz, H-1), 4.00 (t, 1H, *J*_{4,5} 9.6 Hz, H-4), 3.92-3.79 (m, 4H, H-2, H-6a, H-6b, H-6'b), 3.90 (m, 1H, CH₂O), 3.71 (dt, 1H, *J*_{5',6'a}=*J*_{5',6'b} 6.6 Hz, H-5'), 3.59-3.43 (m, 2H, H-5, H-6'a), 3.52 (dt, 1H, *J*_{vic} 6.7 Hz, *J*_{gem} 11.0 Hz, CH₂O), 3.35 (t, 2H, *J*_{vic} 6.7 Hz, CH₂N₃), 2.00, 1.93, 1.86, 1.85 (4s, each 3H, 4×MeCOO), 1.79 (m, 2H, CH₂), 1.72 (s, 3H, MeCON), 0.94 (s, 9H, Me₃C), 0.14, 0.12 (2s, each 3H, Me₂Si); ¹³CNMR (62.9 MHz, CD₃CN): δ 171.0-170.2 (5×C=O), 166.6 (PhCO), 133.9, 130.4, 129.3 (Ar-CH), 131.3 (Ar-C), 101.5 (C-1), 100.8 (C-1'), 76.0 (C-5), 75.5 (C-4), 74.4 (C-3), 71.5 (C-3'), 71.4 (C-5'), 70.0 (C-2'), 67.9 (C-4'), 66.8 (CH₂O), 62.0 (C-6), 61.6 (C-6'), 54.7 (C-2), 48.8 (CH₂N₃), 29.5 (CH₂), 26.2 (Me₃C), 23.0 (MeCON), 20.9-20.5 (4×MeCOO), 18.8 (Me₃C), -4.86, -5.07 (Me₂Si). Anal. Found: C, 53.54; H, 6.65; N, 6.60. Calc for C₃₈H₅₆N₄O₁₆Si (852.96): C, 53.51; H, 6.62; N, 6.57.

3-Azidopropyl 4-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-2-acetamido-3-O-benzyl-6-O-*t*-butyldimethylsilyl-2-deoxy- β -D-glucopyranoside (34).

A solution of acceptor **23** (412 mg, 0.81 mmol, 1 eq) and donor **29** (599 mg, 1.22 mmol, 1.5 eq) in dry CH₂Cl₂ (12.5 mL) was treatment with AW-300 MS (621 mg) and TMSOTf (73 μ L, 0.405 mmol, 0.5 eq) in accordance with the general procedure A. The reaction was stirred until the acceptor was disappeared (4 h, TLC, 7:3 CH₂Cl₂-EtOAc). Purification of the crude product by chromatography on silica (1:1 hexane-EtOAc +

0.1% Et₃N) gave pure disaccharide **34** (489 mg, 72%) as a white foam, *R_f* 0.16 (1:1 toluene-EtOAc), [α]_D -10.63 (*c* 1.05 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ _H 7.38-7.24 (m, 5H, Ar-*H*), 6.51 (d, 1H, *J*_{2,NH} 9.2 Hz, *NH*), 5.32 (dd, 1H, *J*_{3',4'} 3.3 Hz, *J*_{4',5'} 0.9 Hz, H-4'), 4.09 (dd, 1H, *J*_{1',2'} 7.5 Hz, *J*_{2',3'} 10.4 Hz, H-2'), 5.00 (dd, 1H, H-3'), 4.86-4.56 (AB system, 2H, *J*_{A,B} 10.7 Hz, CH₂Ph), 4.85 (d, 1H, H-1'), 4.37 (d, 1H, *J*_{1,2} 8.2 Hz, H-1), 4.04 (dd, 1H, *J*_{5',6'b} 4.8 Hz, *J*_{6'a,6'b} 12.5 Hz, H-6'b), 3.98 (dd, 1H, *J*_{3,4} 10.2 Hz, *J*_{4,5} 9.4 Hz, H-4), 3.94-3.83 (m, 4H, H-6a, H-6b, H-5', H-6'a), 3.80 (dt, 1H, *J*_{vic} 5.8 Hz, *J*_{gem} 10.2 Hz, CH₂O), 3.67 (ddd, 1H, *J*_{2,3} 10.1 Hz, H-2), 3.52 (dt, 1H, *J*_{vic} 6.2 Hz, *J*_{gem} 10.2 Hz, CH₂O), 3.50 (dd, 1H, H-3), 3.34 (t, 2H, *J*_{vic} 6.8 Hz, CH₂N₃), 3.28 (dt, 1H, *J*_{5,6a}=*J*_{5,6'b} 2.2 Hz, H-5), 1.95, 1.94, 1.92, 1.91 (4s, each 3H, 4×MeCOO), 1.85 (s, 3H, MeCON), 1.79 (m, 2H, CH₂), 0.93(s, 9H, Me₃C), 0.12 (s, each 3H, Me₂Si); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.1, 170.9, 170.7, 170.6, 170.4 (5×C=O), 140.1 (Ar-C), 128.9, 128.2 (Ar-CH), 102.0 (C-1), 100.7 (C-1'), 80.6 (C-3), 76.3 (C-5), 76.2 (C-4), 73.8 (CH₂Ph), 71.7 (C-3'), 71.6 (C-5'), 70.3 (C-2'), 68.3 (C-4'), 66.6 (CH₂O), 62.3 (C-6'), 62.2 (C-6), 55.0 (C-2), 48.8 (CH₂N₃), 29.6 (CH₂), 26.3 (Me₃C), 23.3 (MeCON), 21.0-20.8 (4×MeCOO), 18.9 (Me₃C), -4.82, -5.08 (Me₂Si). Anal. Found: C, 54.44; H, 7.01; N, 6.72. Calc for C₃₈H₅₆N₄O₁₅Si (838.98): C, 54.40; H, 6.97; N, 6.68.

Methyl 4-O-(2,3,4-tetra-O-acetyl-6-azido-6-deoxy-β-D-galactopyranosyl)-2-acetamido-3-O-benzyl-6-O-*t*-butyldimethyl-silyl-2-deoxy-β-D-glucopyranoside (35).

A solution of acceptor **21** (193 mg, 0.44 mmol, 1 eq) and donor **30** (315 mg, 0.66 mmol, 1.5 eq) in dry CH₂Cl₂ (7.5 mL) was treatment with AW-300 MS (380 mg) and TMSOTf (40 μL, 0.22 mmol, 0.5 eq) in dry CH₂Cl₂ (0.5 mL) in accordance with the general procedure A. The reaction was stirred until the acceptor was disappeared (12 h, TLC, 4:6 CH₂Cl₂-EtOAc). Purification of the crude product by chromatography on silica (7:3 AcOEt-CH₂Cl₂) gave pure disaccharide **35** (189 mg, 57%) as a white foam, *R_f* 0.39 (6:4 CH₂Cl₂-EtOAc), [α]_D -26.4 (*c* 1.0 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 7.37-7.31 (m, 5H, Ar-*H*), 6.70 (d, 1H, *J*_{2,NH} 9.3 Hz, *NH*), 5.29 (dd, 1H, *J*_{3',4'} 3.3 Hz, *J*_{4',5'} 1.1 Hz, H-4'), 5.09 (dd, 1H, *J*_{2',3'} 10.4 Hz, *J*_{1',2'} 7.6 Hz, H-4'), 5.01 (dd, 1H, H-4'), 4.91, 4.58 (AB system, 2H, *J*_{A,B} 10.9 Hz, CH₂Ph), 4.86 (d, 1H, H-1'), 4.29 (d, 1H, *J*_{1,2} 8.1 Hz, H-1), 3.95 (dd, 1H, *J*_{3,4} 10.0 Hz, *J*_{4,5} 8.6 Hz, H-4), 3.64 (ddd, *J*_{2,3} 8.4 Hz, 1H, H-2), 3.92-3.84 (m, 3H, H-5, H-6a, H-6b), 3.83 (m, 1H, H-5'), 3.48 (dd, 1H, H-3), 3.37 (s, 3H, OMe), 3.30 (dd, 1H, *J*_{6'a,6'b} 12.3 Hz, *J*_{5',6'b} 5.2 Hz, H-6'b), 3.09 (dd, 1H, *J*_{5',6'a} 4.7 Hz, H-6'a), 2.09,

2.04, 1.92, (3s, each 3H, 3×MeCOO), 1.85 (s, 3H, MeCON), 0.94 (s, 9H, Me₃C), 0.12, 0.11 (2s, each 3H, Me₂Si); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.2-170.5 (4×C=O), 140.1 (Ar-C), 128.9-128.2 (Ar-CH), 102.8 (C-1), 100.5 (C-1'), 80.8 (C-3), 76.2 (C-4), 76.1 (C-5), 74.6 (CH₂Ph), 73.1 (C-5'), 71.6 (C-3'), 70.3 (C-2'), 68.8 (C-4'), 62.1 (C-6), 56.6 (OMe), 55.1 (C-2), 50.9 (C-6'), 26.2 (Me₃C), 23.3 (MeCON), 21.0-20.7 (3×MeCOO), 18.8 (Me₃C), -4.87, -5.12 (Me₂Si). Anal. Found: C, 54.27; H, 6.99; N, 7.49. Calc for C₃₄H₅₄N₄O₁₃Si (752.89): C, 54.24; H, 6.96; N, 7.44.

General procedure B for the preparation of lactosamine acceptor 36-40.

A solution of appropriate protected disaccharide **31-35** (1 mmol) in 70% aq AcOH (58 mL) was stirred at 70 °C until the TLC analysis revealed the complete reaction of the starting material with formation of slower moving products. The solution was then cooled to room temperature and repeatedly co-evaporated with toluene (4×30 mL) under diminished pressure. Purification of the crude residue by flash chromatography on silica gel affording the lactosamine acceptors pure **36-40**.

Methyl 4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-acetamido-3-O-benzoyl-2-deoxy-β-D-glucopyranoside (36).

Selective hydrolysis of **31** (220 mg, 0.28 mmol) was performed according to the general procedure B. The reaction was stopped after 1 h (TLC, EtOAc) and the crude product was purified by flash chromatography (95:5 CH₃Cl-MeOH) to give acceptor pure **36** (156 mg, 83%) as a white foam, *R*_f 0.23 (95:5 CHCl₃-MeOH), [α]_D -8.13 (c 1.0 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN-CDCl₃): δ 8.03-7.96 (m, 2H, Ar-*H*), 7.61-7.54 (m, 1H, Ar-*H*), 7.48-7.40 (m, 2H, Ar-*H*), 6.64 (d, 1H, *J*_{2,NH} 9.5 Hz, *NH*), 5.26 (dd, 1H, *J*_{2,3} 10.6 Hz, *J*_{3,4} 9.1 Hz, H-3), 5.10 (dd, 1H, *J*_{3',4'} 3.3 Hz, *J*_{4',5'} 1.2 Hz, H-4'), 4.93 (dd, 1H, *J*_{2',3'} 10.3 Hz, H-3'), 4.85 (dd, 1H, *J*_{1',2'} 7.6 Hz, H-2'), 4.66 (d, 1H, H-1'), 4.51 (d, 1H, *J*_{1,2} 8.5 Hz, H-1), 4.02-3.90 (m, 2H, H-4, H-2), 3.82 (dd, 1H, *J*_{6'a,6'b} 12.1 Hz, *J*_{5',6'b} 2.0 Hz, H-6'b), 3.71-3.63 (m, 2H, H-6'a, H-6b), 3.51-3.40 (m, 3H, H-5', H-5, OH-6), 3.44 (s, 3H, OMe), 3.31 (dd, 1H, *J*_{6a,6b} 11.0 Hz, *J*_{5,6a} 6.0 Hz, H-6a), 2.02, 1.91, 1.88, 1.86 (4s, each 3H, MeCOO), 1.72 (s, 3H, MeCON); ¹³C NMR (62.9 MHz, CD₃CN-CDCl₃): δ 170.8-170.2 (5×MeCO), 166.4 (PhCO), 133.8, 130.2, 129.1 (Ar-CH), 130.9 (Ar-C), 102.2 (C-1), 101.1 (C-1'), 76.2 (C-4), 75.7 (C-5), 74.6 (C-3), 71.3 (C-3'), 70.9 (C-5'), 69.8 (C-2'), 67.5 (C-4'), 61.0 (C-6), 60.7 (C-6'), 56.0 (MeO), 54.5 (C-2), 23.1 (MeCON), 20.9, 20.7,

20.6, 20.5 (4×MeCOO). Anal. Found: C, 53.83; H, 5.89; N, 2.12. Calc for C₃₀H₃₉NO₁₆ (669.63): C, 53.81; H, 5.87; N, 2.09.

Methyl 4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-acetamido-3-O-benzyl-2-deoxy-β-D-glucopyranoside (37).

Selective hydrolysis of **32** (525 mg, 0.68 mmol) was performed according to the general procedure B. The reaction was stopped after 2 h (TLC, EtOAc) and the crude product was purified by flash chromatography (95:5 CH₃Cl-MeOH) to give acceptor pure **37** (371 mg, 83%) as a white foam, *R*_f 0.22 (3:7 hexane-EtOAc), [α]_D -6.13 (c 1.06 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 7.37-7.21 (m, 5H, Ar-*H*), 6.59 (d, 1H, *J*_{2,NH} 9.3 Hz, NH), 5.30 (dd, 1H, *J*_{3',4'} 3.1 Hz, *J*_{4',5'} 0.9 Hz, H-4'), 5.13-5.01 (m, 2H, H-2', H-3'), 4.86, 4.56 (AB system, 2H, *J*_{A,B} 10.8 Hz, CH₂Ph), 4.80 (d, 1H, *J*_{1',2'} 7.9 Hz, H-1'), 4.32 (d, 1H, *J*_{1,2} 8.2 Hz, H-1), 4.02-3.83 (m, 4H, H-5', H-6'a, H-6'b, H-4), 3.81-3.62 (m, 3H, H-2, H-6a, H-6b), 3.53 (dd, 1H, *J*_{2,3} 8.7 Hz, *J*_{3,4} 10.1 Hz, H-3), 3.40 (s, 3H, OMe), 3.30 (ddd, 1H, *J*_{4,5} 9.5 Hz, *J*_{5,6a} 2.3 Hz, *J*_{5,6a} 4.3 Hz, H-5), 3.10 (bt, 1H, OH-6), 2.09, 2.04, 1.91, 1.89 (4s, each 3H, 4×MeCOO), 1.84 (s, 3H, MeCON); ¹³C NMR (62.9 MHz, CD₃CN): δ 171.0, 170.9, 170.8, 170.7, 170.4 (5×C=O), 139.9 (Ar-C), 128.9-128.1 (Ar-CH), 102.8 (C-1), 101.0 (C-1'), 80.9 (C-3), 77.1 (C-4), 76.2 (C-5), 73.9 (CH₂Ph), 71.6 (C-3'), 71.3 (C-5'), 70.3 (C-2'), 68.1 (C-4'), 61.9 (C-6'), 61.1 (C-6), 56.8 (OMe), 54.9 (C-2), 23.3 (MeCON), 20.9-20.8 (4×MeCOO). Anal. Found: C, 54.99; H, 6.34; N, 2.18. Calc for: C₃₀H₄₁NO₁₅ (655.65): C, 54.96; H, 6.30; N, 2.14.

3-Azidopropyl 4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-acetamido-3-O-benzoyl-2-deoxy-β-D-glucopyranoside (38).

Selective hydrolysis of **33** (290 mg, 0.34 mmol) was performed according to the general procedure B. The reaction was stopped after 2 h (TLC, EtOAc) and the crude product was purified by flash chromatography (1:9 hexane-EtOAc) to give acceptor pure **38** (242 mg, 96%) as a white foam, *R*_f 0.34 (EtOAc), [α]_D -15.58 (c 1.2 in CHCl₃), ¹H NMR (250.13 MHz, CD₃CN): δ 8.04-8.00 (m, 2H, Ar-*H*), 7.62-7.54 (m, 1H, Ar-*H*), 7.51-7.42 (m, 2H, Ar-*H*), 6.58 (d, 1H, *J*_{2,NH} 9.5 Hz, NH), 5.27 (dd, 1H, *J*_{2,3} 10.6 Hz, *J*_{3,4} 9.2 Hz, H-3), 5.10 (dd, 1H, *J*_{3',4'} 3.4 Hz, *J*_{4',5'} 1.2 Hz, H-4'), 4.95 (dd, 1H, *J*_{2',3'} 10.4 Hz, H-3'), 4.84 (dd, 1H, *J*_{1',2'} 7.7 Hz, H-2'), 4.64 (d, 1H, H-1'), 4.60 (d, 1H, *J*_{1,2} 8.5 Hz, H-1), 3.96 (dd, 1H, *J*_{4,5} 9.8 Hz, H-4), 3.89 (m, 1H, H-2), 3.84 (m, 1H, CH₂O), 3.78 (m, 1H, H-6'b), 3.69

(m, 1H, H-6'a), 3.69 (m, 1H, H-5'), 3.57 (dt, 1H, J_{vic} 6.3 Hz, J_{gem} 10.3 Hz, CH_2O), 3.46 (ddd, 1H, $J_{6a,6b}$ 11.1 Hz, $J_{5,6b}$ 7.4 Hz, H-6b), 3.44 (m, 1H, H-5), 3.28 (m, 1H, H-6a), 3.36 (t, 2H, J_{vic} 6.8 Hz, CH_2N_3), 3.10 (bt, 1H, $J_{\text{OH},6a}=J_{\text{OH},6b}$ 5.0 Hz, OH-6), 2.02, 1.91, 1.89, 1.86 (4s, each 3H, 4×*Me*COO), 1.78 (m, 2H, CH_2), 1.71 (s, 3H, *Me*CON); ^{13}C NMR (62.9 MHz, CD_3CN): δ 171.0-170.5 (5×C=O), 166.6 (PhCO), 134.1, 130.4, 129.4 (Ar-CH), 131.2 (Ar-C), 101.5 (C-1), 101.3 (C-1'), 76.5 (C-4), 76.0 (C-5), 74.7 (C-3), 71.5 (C-3'), 71.1 (C-5'), 70.0 (C-2'), 67.8 (C-4'), 67.0 (CH_2O), 61.2 (C-6), 60.9 (C-6'), 54.8 (C-2), 48.8 (CH_2N_3), 29.5 (CH_2), 23.0 (*Me*CON), 20.9-20.6 (4×*Me*COO). Anal. Found: C, 52.06; H, 5.76; N, 7.62. Calc for $\text{C}_{32}\text{H}_{42}\text{N}_4\text{O}_{16}$ (738.70): C, 52.03; H, 5.73; N, 7.58.

3-Azidopropyl 4-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-2-acetamido-3-O-benzyl-2-deoxy- β -D-glucopyranoside (39).

Selective hydrolysis of **34** (135 mg, 0.161 mmol) was performed according to the general procedure B. The reaction was stopped after 1.5 h (TLC, EtOAc) and the crude product was purified by flash chromatography (1:9 hexane-EtOAc) to give acceptor pure **39** (94 mg, 81%) as a white foam, R_f 0.28 (EtOAc), $[\alpha]_D$ -9.9 (c 1.10 in CHCl_3), ^1H NMR (250.13 MHz, CD_3CN): δ 7.36-7.25 (m, 5H, Ar-*H*), 6.60 (d, 1H, $J_{2,\text{NH}}$ 9.3 Hz, NH), 5.30 (dd, 1H, $J_{3',4'}$ 3.1 Hz, $J_{4',5'}$ 0.9 Hz, H-4'), 5.12-5.03 (m, 2H, H-2', H-3'), 4.86, 4.57 (AB system, 2H, $J_{A,B}$ 10.8 Hz, CH_2Ph), 4.81 (d, 1H, $J_{1',2'}$ 7.9 Hz, H-1'), 4.40 (d, 1H, $J_{1,2}$ 8.3 Hz, H-1), 4.01 (m, 1H, CH_2O), 3.98 (m, 1H, H-5'), 3.91-3.80 (m, 3H, H-4, H-6'a, H-6'b), 3.79-3.65 (m, 2H, H-6a, H-6b), 3.71 (m, 1H, $J_{2,3}$ 8.7 Hz, H-2), 3.53 (dd, 1H, $J_{3,4}$ 10.2 Hz, H-3), 3.52 (dt, 1H, J_{vic} 6.4 Hz, J_{gem} 10.2 Hz, CH_2O), 3.34 (t, 2H, J_{vic} 6.7 Hz, CH_2N_3), 3.30 (ddd, 1H, $J_{4,5}$ 9.5 Hz, $J_{5,6a}$ 2.3 Hz, $J_{5,6b}$ 4.4 Hz, H-5), 2.09, 2.04, 1.91, 1.89 (4s, each 3H, 4×*Me*COO), 1.84 (s, 3H, *Me*CON), 1.77 (m, 2H, CH_2); ^{13}C NMR (62.9 MHz, CD_3CN): δ 171.1-170.5 (5×C=O), 140.0 (Ar-C), 128.9-128.2 (Ar-CH), 102.0 (C-1), 101.1 (C-1'), 80.9 (C-3), 77.2 (C-4), 76.5 (C-5), 74.0 (CH_2Ph), 71.6 (C-3'), 71.4 (C-5'), 70.3 (C-2'), 68.2 (C-4'), 66.8 (CH_2O), 62.0 (C-6'), 61.2 (C-6), 55.1 (C-2), 48.8 (CH_2N_3), 29.6 (CH_2), 23.3 (*Me*CON), 21.0-20.8 (4×*Me*CO). Anal. Found: C, 52.06; H, 6.15; N, 7.76. Calc for $\text{C}_{32}\text{H}_{44}\text{N}_4\text{O}_{15}$ (724.28): C, 52.03; H, 6.12; N, 7.73.



Methyl 4-O-(2,3,4-tetra-O-acetyl-6-azido-6-deoxy- β -D-galactopyranosyl)-2-acetamido-3-O-benzyl-2-deoxy- β -D-glucopyranoside (40).



Selective hydrolysis of **35** (158 mg, 0.21 mmol) was performed according to the general procedure B. The reaction was stopped after 1 h (TLC, EtOAc) and the crude product was purified by flash chromatography (1:9 hexane-EtOAc) to give acceptor pure **40** (123 mg, 92%) as a white foam, R_f 0.27 (95:5 EtOAc-MeOH), $[\alpha]_D^{25}$ -14.5 (c 1.0 in CHCl_3), ^1H NMR (250.13 MHz, CD_3CN): δ 7.36-7.30 (m, 5H, Ar-*H*), 6.73 (d, 1H, $J_{2,\text{NH}}$ 9.3 Hz, NH), 5.28 (dd, 1H, $J_{3',4'}$ 3.0 Hz, $J_{4',5'}$ 1.1 Hz, H-4'), 5.12-5.02 (m, 2H, H-2', H-3'), 4.90, 4.57 (AB system, 2H, $J_{A,B}$ 10.9 Hz, CH_2Ph), 4.81 (d, 1H, $J_{1',2'}$ 7.9 Hz, H-1'), 4.30 (d, 1H, $J_{1,2}$ 8.2 Hz, H-1), 3.86 (dd, 1H, $J_{3,4}$ 10.1 Hz, $J_{4,5}$ 8.9 Hz, H-4), 3.84 (m, 1H, H-5'), 3.80 (dd, 1H, $J_{6a,6b}$ 12.2 Hz, $J_{5,6b}$ 2.2 Hz, H-6b), 3.67 (dd, 1H, $J_{5,6a}$ 8.8 Hz, H-6a), 3.65 (m, 1H, H-2), 3.50 (dd, 1H, $J_{2,3}$ 8.6 Hz, H-3), 3.31 (ddd, 1H, H-5), 3.28 (dd, 1H, $J_{6'a,6'b}$ 12.8 Hz, $J_{5',6'b}$ 7.4 Hz, H-6'b), 3.12 (dd, 1H, $J_{5',6'a}$ 5.5 Hz, H-6'a), 3.39 (s, 3H, OMe), 2.10, 2.04, 1.92 (3s, each 3H, 3×MeCOO), 1.84 (s, 3H, MeCON); ^{13}C NMR (62.9 MHz, CD_3CN): δ 171.3, 171.2, 170.9, 170.7 (4×C=O), 140.1 (Ar-C), 129.0-128.2 (Ar-CH), 102.9 (C-1), 100.8 (C-1'), 81.1 (C-3), 77.1 (C-4), 76.3 (C-5), 74.5 (CH_2Ph), 72.6 (C-3'), 72.5 (C-5'), 70.4 (C-2'), 68.8 (C-4'), 61.1 (C-6), 56.9 (OMe), 55.2 (C-2), 50.8 (C-6'), 23.3 (MeCON), 21.0-20.8 (3×MeCOO). Anal. Found: C, 52.75; H, 6.08; N, 8.82. Calc for $\text{C}_{28}\text{H}_{38}\text{N}_4\text{O}_{13}$ (638.63): C, 52.71; H, 6.05; N, 8.79.



References



- [1] Gudmundsdottir, A.V.; Nitz, M. Protecting Group Free Glycosidations Using *p*-Toluenesulfonohydrazide Donors. *Org. Lett.* **2008**, *10*, 3461-3463. doi: 10.1021/ol801232f.
- [2] Mulard, L.A.; Costachel C.; Sansonetti P.J. Synthesis of the Methyl Glycosides of a Di- and Two Trisaccharide Fragments Specific for the *Shigella flexneri* Serotype 2a O-Antigen. *J. Carbohydr. Chem.* **2000**, *19*, 849-877. doi: 10.1080/07328300008544123.
- [3] Willems, M.M.J.H.P.; Zom, G.G.; Meeuwenoord, N.; Ossendorp, F.A.; Overkleeft, H.S.; van der Marel, G.A.; Codée J.D.C.; Filippov, D.V. Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates. *Beilstein J. Org. Chem.* **2014**, *10*, 1445-1453. doi: 10.3762/bjoc.10.148.
- [4] Umezawa, S.; Tsuchiya, T.; Tatsuta, K. Studies of Aminosugars. XI. Configurational Studies of Aminosugar Glycosides and Aminocyclitols by a Copper Complex Method. *Bull. Chem. Soc. Jap.* **1966**, *39*, 1235-1243. doi: 10.1246/bcsj.39.1235



- [5] Cai, Y.; Ling C.-C.; Bundle, D.R. Concise and Efficient Synthesis of 2-Acetamido-2-deoxy- β -D-hexopyranosides of Diverse Aminosugars from 2-Acetamido-2-deoxy- β -D-glucose. *J. Org. Chem.* **2009**, *74*, 580-589. doi:10.1021/jo801927k
- [6] Yoshino, T.; Reuter, G.; Kelm S.; Schauer, R. Facile synthesis of 2'-substituted lactoses. *Glycoconjugate J.*, **1986**, *3*, 7-14. doi: 10.1007/BF01108607.

















COSY spectra of **20** (250.13 MHz, CD₃CN)





HETCOR spectra of **20** (62.9 MHz, CD₃CN)













COSY spectra of **22** (250.13 MHz, CD₃CN)







HETCOR spectra of **22** (62.9 MHz, CD₃CN)






COSY spectra of **23** (250.13 MHz, CD₃CN)








HETCOR spectra of **25** (62.9 MHz, CD₃CN)




COSY spectra of **25** (250.13 MHz, CD₃CN)










COSY spectra of **26** (250.13 MHz, CD₃CN)






¹H NMR of **27** (250.13 MHz, CD₃CN)















































































COSY of **44** (250.13 MHz, CD₃CN)








HETCOR of **44** (62.9 MHz, CD₃CN)









































COSY spectra of **50** (250.13 MHz, CDCl₃-CD₃OD)






HETCOR spectra of **50** (62.9 MHz, CDCl₃-CD₃OD)
















^1H NMR of **2** (600 MHz, D_2O)













¹H NMR of **3** (600 MHz, D₂O)





^1H NMR of **3** (600 MHz, D_2O)













^1H NMR of **5** (600 MHz, D_2O)




COSY spectra of **5** (600 MHz, D_2O)



HSQC spectra of **5** (600 MHz D₂O)



^{13}C NMR of **6** (62.9 MHz, $\text{CD}_3\text{OD}-\text{D}_2\text{O}$)



^1H NMR of **7** (250.13 MHz, D_2O)

